Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.42 |
| ▸ | EP300 | Q09472 | 7/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788175 | 0.89 | MAPK1 (0.51) | MAPK1SRCPKMATMHSD17B10 | |
| SCHEMBL23069262 | 0.86 | CYP19A1 (0.47) | MAPK1SRCPKMATMHSD17B10 | |
| SCHEMBL15121329 | 0.86 | SRC (0.47) | MAPK1SRCPKMATMHSD17B10 | |
| SCHEMBL16612208 | 0.86 | MAPK1 (0.45) | MAPK1SRCPKMATMHSD17B10 | |
| SCHEMBL12847886 | 0.85 | SRC (0.44) | MAPK1SRCPKMATMHSD17B10 | |
| SCHEMBL27646903 | 0.84 | P2RX7 (0.45) | NOTUMP2RX7 | |
| SCHEMBL16033032 | 0.84 | GGPS1 (0.48) | MAPK1SRCEP300 | |
| SCHEMBL21063655 | 0.84 | SRC (0.44) | MAPK1SRCPKMATMHSD17B10 | |
| SCHEMBL14104171 | 0.82 | SRC (0.43) | MAPK1SRCPKMATMHSD17B10 | |
| SCHEMBL908777 | 0.82 | MAPK1 (0.50) | MAPK1SRCPKMATMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114616227-A | Nitrification inhibitors | 墨尔本大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114616227-A | Nitrification inhibitors | 墨尔本大学 | 2022-06-10 | — | — | CN | disclosed |
| EP-3347008-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11046716-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046716-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200055877-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-20 | — | — | US | disclosed |
| US-20200055877-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-20 | — | — | US | disclosed |
| US-10399996-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399996-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3347008-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20170073360-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
| US-20170073360-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
| US-20170073360-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
| WO-2017044828-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044828-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-03-16 | — | — | WO | disclosed |
| EP-2857388-A1 | Azoles containing sulfone | Grünenthal GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
| EP-2857388-A1 | Azoles containing sulfone | Grünenthal GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399996-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | MAPK1 4548/4885SRC 4206/4885PKM 2485/4885 |
| US-20170073360-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MAPK1 4548/4885SRC 4206/4885PKM 2485/4885 |
| US-20200055877-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MAPK1 4548/4885SRC 4206/4885PKM 2485/4885 |
| US-11046716-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | MAPK1 4548/4885SRC 4206/4885PKM 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.